Enlivex Therapeutics receives notice of allowance from Japanese Patent Office

Enlivex Therapeutics (ENLV) announced that the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861 titled “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. Once issued, the resulting patent will provide Enlivex with added intellectual property protection through at least 2040. The Company expects that this new patent will be formally issued in Japan by the end of the second quarter of 2025. Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex, commented, “this notice of allowance demonstrates our commitment to protecting Allocetra’s commercial opportunities in key geographies around the world. We also believe that it highlights the successful execution of our global IP strategy. Going forward, we will continue to pursue multiple layers of patent protection in key global markets as we work to develop Allocetra as a next generation cell therapy for osteoarthritis, which is an unmet medical need that currently has poor treatment alternatives.”